Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Share-based Compensation (2018 - 2025)

Historic Share-based Compensation for Precision Biosciences (DTIL) over the last 8 years, with Q3 2025 value amounting to $2.4 million.

  • Precision Biosciences' Share-based Compensation fell 2541.42% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.7 million, marking a year-over-year decrease of 239.11%. This contributed to the annual value of $12.6 million for FY2024, which is 1022.79% down from last year.
  • Per Precision Biosciences' latest filing, its Share-based Compensation stood at $2.4 million for Q3 2025, which was down 2541.42% from $2.9 million recorded in Q2 2025.
  • Precision Biosciences' Share-based Compensation's 5-year high stood at $5.1 million during Q2 2022, with a 5-year trough of $2.4 million in Q3 2025.
  • For the 5-year period, Precision Biosciences' Share-based Compensation averaged around $3.7 million, with its median value being $3.6 million (2021).
  • As far as peak fluctuations go, Precision Biosciences' Share-based Compensation soared by 3187.89% in 2022, and later tumbled by 3950.91% in 2023.
  • Quarter analysis of 5 years shows Precision Biosciences' Share-based Compensation stood at $4.4 million in 2021, then grew by 2.28% to $4.5 million in 2022, then tumbled by 34.55% to $3.0 million in 2023, then grew by 20.28% to $3.6 million in 2024, then tumbled by 33.18% to $2.4 million in 2025.
  • Its Share-based Compensation was $2.4 million in Q3 2025, compared to $2.9 million in Q2 2025 and $2.8 million in Q1 2025.